PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25925126-6 2015 Since in most cancer cells survival pathways counteract the effects of TRAIL-induced RCD, sensitizers such as cycloheximide (CHX) are frequently added in cell culture to overcome this problem. Cycloheximide 110-123 TNF superfamily member 10 Homo sapiens 71-76 27602497-6 2016 At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide. Cycloheximide 139-152 TNF superfamily member 10 Homo sapiens 40-45 21440540-2 2011 In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF. Cycloheximide 152-155 TNF superfamily member 10 Homo sapiens 27-32 23470529-8 2013 Such upregulation of c-FLIPS was rapidly reduced and TRAIL sensitivity was restored by treatment with cycloheximide. Cycloheximide 102-115 TNF superfamily member 10 Homo sapiens 53-58 21440540-2 2011 In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF. Cycloheximide 152-155 TNF superfamily member 10 Homo sapiens 33-38 21440540-2 2011 In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF. Cycloheximide 152-155 TNF superfamily member 10 Homo sapiens 33-38 18202809-4 2008 Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126). Cycloheximide 119-132 TNF superfamily member 10 Homo sapiens 61-66 20811726-9 2010 Treatment with the protein synthesis inhibitor cycloheximide sensitized SW948-TR to rhTRAIL-induced apoptosis, indicating that the functionality of the TRAIL receptors was maintained. Cycloheximide 47-60 TNF superfamily member 10 Homo sapiens 86-91 18202809-4 2008 Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126). Cycloheximide 134-137 TNF superfamily member 10 Homo sapiens 61-66 17097066-2 2006 The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide. Cycloheximide 69-82 TNF superfamily member 10 Homo sapiens 13-18 18065493-7 2007 We show that TRAIL activates the canonical caspase-dependent pathway, whereas treatment with cycloheximide increases the sensitivity of MG-63 cells to TRAIL and anti-DR5 and can also sensitize hPOB-tert cells to both agents. Cycloheximide 93-106 TNF superfamily member 10 Homo sapiens 151-156 17938269-2 2007 We previously showed that resistant malignant mesothelioma cells are sensitized to TRAIL-induced apoptosis by diverse toxic insults including chemotherapy, irradiation, or protein translation inhibitors such as cycloheximide. Cycloheximide 211-224 TNF superfamily member 10 Homo sapiens 83-88 15806306-6 2005 IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis. Cycloheximide 56-69 TNF superfamily member 10 Homo sapiens 210-215 16003319-12 2005 Combined treatment with cycloheximide and TRAIL induced cleaved forms of caspases and simultaneously restored the sensitivity to TRAIL-induced apoptosis in the resistant cells. Cycloheximide 24-37 TNF superfamily member 10 Homo sapiens 129-134 16003319-14 2005 Suppression of FLIP-S by cycloheximide restored sensitivity to TRAIL-induced apoptosis in resistant cancer cells. Cycloheximide 25-38 TNF superfamily member 10 Homo sapiens 63-68 15614529-1 2005 Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), by treatment with cycloheximide (CHX). Cycloheximide 168-181 TNF superfamily member 10 Homo sapiens 142-147 15614529-1 2005 Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), by treatment with cycloheximide (CHX). Cycloheximide 183-186 TNF superfamily member 10 Homo sapiens 142-147 15614529-5 2005 Therefore, cycloheximide treatment resulted in an increase in the pro-caspase-8 to cFLIP ratio, which correlated with sensitization to TRAIL-mediated apoptosis. Cycloheximide 11-24 TNF superfamily member 10 Homo sapiens 135-140 15806306-6 2005 IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis. Cycloheximide 71-74 TNF superfamily member 10 Homo sapiens 210-215 14662022-8 2003 As a result, LY294002 or cycloheximide significantly enhanced TRAIL-induced apoptosis. Cycloheximide 25-38 TNF superfamily member 10 Homo sapiens 62-67 15586230-6 2005 The protein synthesis inhibitor cycloheximide markedly increased the TRAIL sensitivity of these cell lines, whereas the CB-specific chemical inhibitor CA-074 markedly reduced the sensitivity of primary OC cells to TRAIL. Cycloheximide 32-45 TNF superfamily member 10 Homo sapiens 69-74 15094781-6 2004 TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner. Cycloheximide 101-114 TNF superfamily member 10 Homo sapiens 0-5 15192330-6 2004 Of note, sensitisation of the Jurkat cells to TRAIL was shown to depend on new protein synthesis, since no enhancement of apoptosis was observed when cells were exposed to both TRAIL and the protein synthesis inhibitor cycloheximide. Cycloheximide 219-232 TNF superfamily member 10 Homo sapiens 46-51 15037583-4 2004 Annexin V staining was also used to determine the capacity of either cycloheximide or interferon-beta to enhance TRAIL-induced apoptosis. Cycloheximide 69-82 TNF superfamily member 10 Homo sapiens 113-118 15037583-7 2004 Cycloheximide exerted a profound effect in enhancing TRAIL-induced apoptosis in all but two of the uveal melanoma cell lines and in all three of the metastases cell lines. Cycloheximide 0-13 TNF superfamily member 10 Homo sapiens 53-58 15033719-1 2003 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in most tumor cells, a process sometimes potentiated by chemotherapeutic drugs or cycloheximide (CHX). Cycloheximide 176-189 TNF superfamily member 10 Homo sapiens 0-55 15033719-1 2003 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in most tumor cells, a process sometimes potentiated by chemotherapeutic drugs or cycloheximide (CHX). Cycloheximide 176-189 TNF superfamily member 10 Homo sapiens 57-62 14632785-10 2003 Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX). Cycloheximide 123-136 TNF superfamily member 10 Homo sapiens 35-40 14632785-10 2003 Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX). Cycloheximide 138-141 TNF superfamily member 10 Homo sapiens 35-40 14632785-12 2003 Down-regulation of XIAP may be responsible for enhancement or restoration of TRAIL sensitivity after CHX treatment in B-lymphocytic leukaemia cells. Cycloheximide 101-104 TNF superfamily member 10 Homo sapiens 77-82 14751030-11 2003 In conclusion, TRAIL in combination with troglitazone, paclitaxel, and cycloheximide induces apoptosis in thyroid cancer cells at suboptimal concentrations that cannot be achieved using TRAIL alone. Cycloheximide 71-84 TNF superfamily member 10 Homo sapiens 15-20 14751030-9 2003 In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not. Cycloheximide 121-134 TNF superfamily member 10 Homo sapiens 15-20 14751030-9 2003 In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not. Cycloheximide 121-134 TNF superfamily member 10 Homo sapiens 45-50 14751030-9 2003 In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not. Cycloheximide 121-134 TNF superfamily member 10 Homo sapiens 45-50 14751030-11 2003 In conclusion, TRAIL in combination with troglitazone, paclitaxel, and cycloheximide induces apoptosis in thyroid cancer cells at suboptimal concentrations that cannot be achieved using TRAIL alone. Cycloheximide 71-84 TNF superfamily member 10 Homo sapiens 186-191 11593415-12 2001 Inhibition of protein synthesis by cycloheximide also causes LNCap cells sensitive to TRAIL. Cycloheximide 35-48 TNF superfamily member 10 Homo sapiens 86-91 12592338-12 2003 Both the cell permeable NF-kappaB inhibitor SN50 and cycloheximide lowered cFLIP(L)expression and restored sentivity of AR cells to TRAIL. Cycloheximide 53-66 TNF superfamily member 10 Homo sapiens 132-137 12488957-9 2002 However, treatment with an inhibitor of protein synthesis (cycloheximide) or with an enzyme (PI-PLC) that can remove TRAIL-R3 from the islet-cell membrane was able to increase the susceptibility of TRAIL-resistant primary islet cells to the TRAIL death pathway. Cycloheximide 59-72 TNF superfamily member 10 Homo sapiens 117-122 12488957-9 2002 However, treatment with an inhibitor of protein synthesis (cycloheximide) or with an enzyme (PI-PLC) that can remove TRAIL-R3 from the islet-cell membrane was able to increase the susceptibility of TRAIL-resistant primary islet cells to the TRAIL death pathway. Cycloheximide 59-72 TNF superfamily member 10 Homo sapiens 198-203 12136286-12 2002 TRAIL failed to kill RPE cells in vitro, but showed a strong synergistic killing effect when coincubated with protein (cycloheximide) or RNA (actinomycin D) synthesis inhibitor. Cycloheximide 119-132 TNF superfamily member 10 Homo sapiens 0-5 12085986-5 2002 Seven of ten HCC cell lines showed resistance to TRAIL-induced apoptosis and five of seven TRAIL-resistant cell lines became sensitive to TRAIL by co-treatment with cycloheximide. Cycloheximide 165-178 TNF superfamily member 10 Homo sapiens 91-96 12085986-5 2002 Seven of ten HCC cell lines showed resistance to TRAIL-induced apoptosis and five of seven TRAIL-resistant cell lines became sensitive to TRAIL by co-treatment with cycloheximide. Cycloheximide 165-178 TNF superfamily member 10 Homo sapiens 91-96 11877293-5 2002 Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels. Cycloheximide 237-250 TNF superfamily member 10 Homo sapiens 151-156 11877293-5 2002 Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels. Cycloheximide 252-255 TNF superfamily member 10 Homo sapiens 151-156 12865931-8 2003 The protein synthesis inhibitor cycloheximide decreased FLICE-like inhibitory protein levels in all cell lines, and the TRAIL-resistant cell lines Caco-2 and Colo320 became sensitive for TRAIL. Cycloheximide 32-45 TNF superfamily member 10 Homo sapiens 187-192 12663665-3 2003 However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis. Cycloheximide 53-66 TNF superfamily member 10 Homo sapiens 205-210 12163389-4 2002 We found that the emergence of resistance to Apo2L/TRAIL, after prolonged incubation with this cytokine, was associated with increased levels of FLICE inhibitory protein (FLIP), and was overcome by cycloheximide and bisindolylmaleimide, that specifically down-regulated FLIP expression, as well as by transfection of a FLIP anti-sense oligonucleotide. Cycloheximide 198-211 TNF superfamily member 10 Homo sapiens 45-50 12163389-4 2002 We found that the emergence of resistance to Apo2L/TRAIL, after prolonged incubation with this cytokine, was associated with increased levels of FLICE inhibitory protein (FLIP), and was overcome by cycloheximide and bisindolylmaleimide, that specifically down-regulated FLIP expression, as well as by transfection of a FLIP anti-sense oligonucleotide. Cycloheximide 198-211 TNF superfamily member 10 Homo sapiens 51-56 11850832-6 2002 The protein synthesis inhibitor cycloheximide significantly enhanced TRAIL toxicity toward PrEC as measured by tetrazolium conversion but had little or no effect on other TRAIL-induced apoptotic responses. Cycloheximide 32-45 TNF superfamily member 10 Homo sapiens 69-74 11461904-9 2001 Treatment of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to TRAIL. Cycloheximide 34-47 TNF superfamily member 10 Homo sapiens 108-113 11533151-4 2001 RID inhibits TRAIL-induced apoptosis when cells are sensitized to TRAIL either by adenovirus infection or treatment with cycloheximide. Cycloheximide 121-134 TNF superfamily member 10 Homo sapiens 13-18 11533151-4 2001 RID inhibits TRAIL-induced apoptosis when cells are sensitized to TRAIL either by adenovirus infection or treatment with cycloheximide. Cycloheximide 121-134 TNF superfamily member 10 Homo sapiens 66-71 11439339-3 2001 Cells were exposed to TRAIL in the presence of cycloheximide which acted as a sensitizer. Cycloheximide 47-60 TNF superfamily member 10 Homo sapiens 22-27 10931534-9 2000 In addition, cycloheximide worked synergistically with TRAIL/Apo-2L to induce apoptosis in glioma cells. Cycloheximide 13-26 TNF superfamily member 10 Homo sapiens 61-67 11004677-10 2000 While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL. Cycloheximide 57-70 TNF superfamily member 10 Homo sapiens 100-105 11004677-10 2000 While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL. Cycloheximide 57-70 TNF superfamily member 10 Homo sapiens 109-114 11004677-10 2000 While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL. Cycloheximide 57-70 TNF superfamily member 10 Homo sapiens 109-114 11004677-10 2000 While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL. Cycloheximide 57-70 TNF superfamily member 10 Homo sapiens 109-114 10823821-1 2000 In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX). Cycloheximide 202-215 TNF superfamily member 10 Homo sapiens 100-105 10823821-1 2000 In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX). Cycloheximide 217-220 TNF superfamily member 10 Homo sapiens 100-105 11359904-6 2001 SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX). Cycloheximide 168-181 TNF superfamily member 10 Homo sapiens 39-76 11359904-6 2001 SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX). Cycloheximide 168-181 TNF superfamily member 10 Homo sapiens 78-83 11359904-6 2001 SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX). Cycloheximide 183-186 TNF superfamily member 10 Homo sapiens 39-76 11359904-6 2001 SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX). Cycloheximide 183-186 TNF superfamily member 10 Homo sapiens 78-83 10945619-10 2000 One medullary carcinoma cell line was resistant to Fas-and TRAIL-induced apoptosis, even in the presence of cycloheximide, and to transfection of constitutively active caspase-8, suggesting a different regulation of the apoptotic pathway. Cycloheximide 108-121 TNF superfamily member 10 Homo sapiens 59-64 10676636-8 2000 These data indicate that an early block of TRAIL-induced apoptosis was present in PK compared with TK or PK treated with CHX. Cycloheximide 121-124 TNF superfamily member 10 Homo sapiens 43-48 35298837-8 2022 The soluble recombinant protein Trx-TNFSF10 could induce cytotoxicity and apoptosis in HeLa cells with cycloheximide as a promoter. Cycloheximide 103-116 TNF superfamily member 10 Homo sapiens 36-43 10918593-3 2000 The tumoricidal effect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines. Cycloheximide 56-59 TNF superfamily member 10 Homo sapiens 26-31 10811114-3 2000 Treatment of PC-3 and DU145 cells with TRAIL caused a rapid apoptotic cell death, whereas tumor necrosis factor-alpha (TNF-alpha) is ineffective unless in the presence of the protein synthesis inhibitor cycloheximide. Cycloheximide 203-216 TNF superfamily member 10 Homo sapiens 39-44 10651020-5 2000 Viability assay performed after exposure to soluble APO2L for 16 h showed that DAOY medulloblastoma cells were the most sensitive and that apoptosis induced by APO2L was greatly enhanced when protein synthesis was inhibited by cycloheximide. Cycloheximide 227-240 TNF superfamily member 10 Homo sapiens 52-57 10651020-5 2000 Viability assay performed after exposure to soluble APO2L for 16 h showed that DAOY medulloblastoma cells were the most sensitive and that apoptosis induced by APO2L was greatly enhanced when protein synthesis was inhibited by cycloheximide. Cycloheximide 227-240 TNF superfamily member 10 Homo sapiens 160-165 31704709-8 2019 Simultaneously, TRAIL-induced de novo translation in resistant cells, when blocked by cycloheximide, abrogated all TRAIL resistance. Cycloheximide 86-99 TNF superfamily member 10 Homo sapiens 16-21 31704709-8 2019 Simultaneously, TRAIL-induced de novo translation in resistant cells, when blocked by cycloheximide, abrogated all TRAIL resistance. Cycloheximide 86-99 TNF superfamily member 10 Homo sapiens 115-120